Botanix FY21 Annual Report

Botanix (ASX:BOT) has today published its its Annual Report for the 2020-2021 Financial Year (FY21)

Key highlights from this financial year include:

• Successful completion of BTX 1801 antimicrobial  Phase 2a  clinical  study, showing two different BTX 1801 formulations were safe, well tolerated and successful at eradicating Staphylococcus Aureus.
• BTX 1702 rosacea clinical study was successfully launched in Australia & New Zealand and is actively recruiting.
• Positive results achieved from the BTX 1204A pilot study of canines with atopic dermatitis, with a larger proof of concept canine study ready to kick off.
• Expansion of the Management team  in  the  US  to  drive  clinical  and  commercial activities across the antimicrobial and dermatology programs.
• Preparation for the BTX 1801 Phase 2b clinical study targeting the nasal decolonisation of Staph aureus in haemodialysis patients is progressing well and is positioned to validate synthetic CBD as a novel new antimicrobial.

Click here to read the report.